194 related articles for article (PubMed ID: 35383885)
1. A two-part, single-arm, multicentre, phase I study of zanubrutinib, a selective Bruton tyrosine kinase inhibitor, in Chinese patients with relapsed/refractory B-cell malignancies.
Song Y; Sun M; Qi J; Xu W; Zhou J; Li D; Li J; Qiu L; Du C; Guo H; Huang J; Tang Z; Ou Y; Wu B; Yu Y; Zhu J
Br J Haematol; 2022 Jul; 198(1):62-72. PubMed ID: 35383885
[TBL] [Abstract][Full Text] [Related]
2. Treatment of relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma with the BTK inhibitor zanubrutinib: phase 2, single-arm, multicenter study.
Xu W; Yang S; Zhou K; Pan L; Li Z; Zhou J; Gao S; Zhou D; Hu J; Feng R; Huang H; Ji M; Guo H; Huang J; Novotny W; Feng S; Li J
J Hematol Oncol; 2020 May; 13(1):48. PubMed ID: 32393328
[TBL] [Abstract][Full Text] [Related]
3. Treatment of Patients with Relapsed or Refractory Mantle-Cell Lymphoma with Zanubrutinib, a Selective Inhibitor of Bruton's Tyrosine Kinase.
Song Y; Zhou K; Zou D; Zhou J; Hu J; Yang H; Zhang H; Ji J; Xu W; Jin J; Lv F; Feng R; Gao S; Guo H; Zhou L; Elstrom R; Huang J; Novotny W; Wei R; Zhu J
Clin Cancer Res; 2020 Aug; 26(16):4216-4224. PubMed ID: 32461234
[TBL] [Abstract][Full Text] [Related]
4. A Phase II Trial of the Bruton Tyrosine-Kinase Inhibitor Zanubrutinib (BGB-3111) in Patients with Relapsed/Refractory Waldenström Macroglobulinemia.
An G; Zhou D; Cheng S; Zhou K; Li J; Zhou J; Xie L; Jin J; Zhong L; Yan L; Guo H; Du C; Zhong J; Yu Y; Wu B; Qiu L
Clin Cancer Res; 2021 Oct; 27(20):5492-5501. PubMed ID: 34253577
[TBL] [Abstract][Full Text] [Related]
5. Zanubrutinib in patients with previously treated B-cell malignancies intolerant of previous Bruton tyrosine kinase inhibitors in the USA: a phase 2, open-label, single-arm study.
Shadman M; Flinn IW; Levy MY; Porter RF; Burke JM; Zafar SF; Misleh J; Kingsley EC; Yimer HA; Freeman B; Rao SS; Chaudhry A; Tumula PK; Gandhi MD; Manda S; Chen DY; By K; Xu L; Liu Y; Crescenzo R; Idoine A; Zhang X; Cohen A; Huang J; Sharman JP
Lancet Haematol; 2023 Jan; 10(1):e35-e45. PubMed ID: 36400069
[TBL] [Abstract][Full Text] [Related]
6. Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL.
Tam CS; Trotman J; Opat S; Burger JA; Cull G; Gottlieb D; Harrup R; Johnston PB; Marlton P; Munoz J; Seymour JF; Simpson D; Tedeschi A; Elstrom R; Yu Y; Tang Z; Han L; Huang J; Novotny W; Wang L; Roberts AW
Blood; 2019 Sep; 134(11):851-859. PubMed ID: 31340982
[TBL] [Abstract][Full Text] [Related]
7. Zanubrutinib in relapsed/refractory mantle cell lymphoma: long-term efficacy and safety results from a phase 2 study.
Song Y; Zhou K; Zou D; Zhou J; Hu J; Yang H; Zhang H; Ji J; Xu W; Jin J; Lv F; Feng R; Gao S; Guo H; Zhou L; Huang J; Novotny W; Kim P; Yu Y; Wu B; Zhu J
Blood; 2022 May; 139(21):3148-3158. PubMed ID: 35303070
[TBL] [Abstract][Full Text] [Related]
8. Cardiovascular events reported in patients with B-cell malignancies treated with zanubrutinib.
Moslehi JJ; Furman RR; Tam CS; Salem JE; Flowers CR; Cohen A; Zhang M; Zhang J; Chen L; Ma H; Brown JR
Blood Adv; 2024 May; 8(10):2478-2490. PubMed ID: 38502198
[TBL] [Abstract][Full Text] [Related]
9. Zanubrutinib for the treatment of relapsed or refractory mantle cell lymphoma.
Tam CS; Opat S; Simpson D; Cull G; Munoz J; Phillips TJ; Kim WS; Rule S; Atwal SK; Wei R; Novotny W; Huang J; Wang M; Trotman J
Blood Adv; 2021 Jun; 5(12):2577-2585. PubMed ID: 34152395
[TBL] [Abstract][Full Text] [Related]
10. Zanubrutinib monotherapy for relapsed or refractory non-germinal center diffuse large B-cell lymphoma.
Yang H; Xiang B; Song Y; Zhang H; Zhao W; Zou D; Lv F; Guo W; Liu A; Li C; Tan Z; Liu Y; Fu L; Guo H; Novotny W; Huang J; Li Y
Blood Adv; 2022 Mar; 6(6):1629-1636. PubMed ID: 34638136
[TBL] [Abstract][Full Text] [Related]
11. Zanubrutinib for the treatment of patients with Waldenström macroglobulinemia: 3 years of follow-up.
Trotman J; Opat S; Gottlieb D; Simpson D; Marlton P; Cull G; Munoz J; Tedeschi A; Roberts AW; Seymour JF; Atwal SK; Yu Y; Novotny W; Holmgren E; Tan Z; Hilger JD; Huang J; Tam CS
Blood; 2020 Oct; 136(18):2027-2037. PubMed ID: 32698195
[TBL] [Abstract][Full Text] [Related]
12. ALPINE: zanubrutinib versus ibrutinib in relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma.
Hillmen P; Brown JR; Eichhorst BF; Lamanna N; O'Brien SM; Qiu L; Salmi T; Hilger J; Wu K; Cohen A; Huang J; Tam CS
Future Oncol; 2020 Apr; 16(10):517-523. PubMed ID: 32207333
[TBL] [Abstract][Full Text] [Related]
13. Zanubrutinib: a new BTK inhibitor for treatment of relapsed/refractory mantle cell lymphoma.
Weaver AN; Jimeno A
Drugs Today (Barc); 2020 Aug; 56(8):531-539. PubMed ID: 33025948
[TBL] [Abstract][Full Text] [Related]
14. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies.
Advani RH; Buggy JJ; Sharman JP; Smith SM; Boyd TE; Grant B; Kolibaba KS; Furman RR; Rodriguez S; Chang BY; Sukbuntherng J; Izumi R; Hamdy A; Hedrick E; Fowler NH
J Clin Oncol; 2013 Jan; 31(1):88-94. PubMed ID: 23045577
[TBL] [Abstract][Full Text] [Related]
15. Zanubrutinib Monotherapy for Naïve and Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: A Pooled Analysis of Three Studies.
Xu W; Yang S; Tam CS; Seymour JF; Zhou K; Opat S; Qiu L; Sun M; Wang T; Trotman J; Pan L; Gao S; Zhou J; Zhou D; Zhu J; Song Y; Hu J; Feng R; Huang H; Su D; Shi M; Li J
Adv Ther; 2022 Sep; 39(9):4250-4265. PubMed ID: 35900694
[TBL] [Abstract][Full Text] [Related]
16. A prospective study of zanubrutinib, a Bruton tyrosine kinase inhibitor, in relapsed/refractory idiopathic multicentric Castleman disease.
Zhang L; Gao YH; Li SY; Zhao H; Zhang MY; Yu YY; Liu YT; Li J
Int J Hematol; 2024 Jun; 119(6):631-637. PubMed ID: 38546960
[TBL] [Abstract][Full Text] [Related]
17. The MAGNOLIA Trial: Zanubrutinib, a Next-Generation Bruton Tyrosine Kinase Inhibitor, Demonstrates Safety and Efficacy in Relapsed/Refractory Marginal Zone Lymphoma.
Opat S; Tedeschi A; Linton K; McKay P; Hu B; Chan H; Jin J; Sobieraj-Teague M; Zinzani PL; Coleman M; Thieblemont C; Browett P; Ke X; Sun M; Marcus R; Portell CA; Ardeshna K; Bijou F; Walker P; Hawkes EA; Mapp S; Ho SJ; Talaulikar D; Zhou KS; Co M; Li X; Zhou W; Cappellini M; Tankersley C; Huang J; Trotman J
Clin Cancer Res; 2021 Dec; 27(23):6323-6332. PubMed ID: 34526366
[TBL] [Abstract][Full Text] [Related]
18. Zanubrutinib for treatment-naïve and relapsed/refractory chronic lymphocytic leukaemia: long-term follow-up of the phase I/II AU-003 study.
Cull G; Burger JA; Opat S; Gottlieb D; Verner E; Trotman J; Marlton P; Munoz J; Johnston P; Simpson D; Stern JC; Prathikanti R; Wu K; Novotny W; Huang J; Tam CS
Br J Haematol; 2022 Mar; 196(5):1209-1218. PubMed ID: 34915592
[TBL] [Abstract][Full Text] [Related]
19. A phase 1 clinical trial of the selective BTK inhibitor ONO/GS-4059 in relapsed and refractory mature B-cell malignancies.
Walter HS; Rule SA; Dyer MJ; Karlin L; Jones C; Cazin B; Quittet P; Shah N; Hutchinson CV; Honda H; Duffy K; Birkett J; Jamieson V; Courtenay-Luck N; Yoshizawa T; Sharpe J; Ohno T; Abe S; Nishimura A; Cartron G; Morschhauser F; Fegan C; Salles G
Blood; 2016 Jan; 127(4):411-9. PubMed ID: 26542378
[TBL] [Abstract][Full Text] [Related]
20. Zanubrutinib for the treatment of adults with Waldenstrom macroglobulinemia.
Sarosiek S; Sermer D; Branagan AR; Treon SP; Castillo JJ
Expert Rev Anticancer Ther; 2022 May; 22(5):471-478. PubMed ID: 35404729
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
